| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V87260 | 17β-HSD5 inhibitor 3 | 948581-46-2 | 17β-HSD5 inhibitor 3 (Compound 31) is an orally active 17β-HSD5 inhibitor with IC50 of 69 nM. |
|
V107007 | 3-Acetyl-7-Hydroxycoumarin | 10441-27-7 | 3-Acetyl-7-hydroxycoumarin (Compound 2) is a highly selective 17-β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. |
|
V135250 | ESC1002755 | 2915567-21-2 | ESC1002755 is a 17β-HSD10 inhibitor with an IC50 of 19 nM. |
|
V116796 | Gatuzosiran sodium | Gatuzosiran sodium is an siRNA that inhibits the synthesis of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) and is used in research on fatty liver disease. | |
|
V136859 | GPI2A sodium scrambled negative control | The GPI2A sodium scrambled negative control is a negative control with the GPI2A sodium ion sequence scrambled. | |
|
V137585 | HSD17B13-IN-105 | 3012624-88-0 | HSD17B13-IN-105 is a selective 17β-hydroxysteroid dehydrogenase 13 (17BHSD13) inhibitor with an IC50 value of 0.036 μM and high selectivity for 17BHSD4 (IC50 value of 31.5 μM). |
|
V83887 | HSD17B13-IN-13 | 2762668-28-8 | |
|
V83902 | HSD17B13-IN-20 | 2919797-59-2 | |
|
V83951 | HSD17B13-IN-21 | 2758802-18-3 | |
|
V83936 | HSD17B13-IN-32 | 2770246-61-0 | |
|
V84153 | HSD17B13-IN-43 | 2770246-11-0 | |
|
V83966 | HSD17B13-IN-49 | 2770246-74-5 | |
|
V84149 | HSD17B13-IN-58 | 2770246-89-2 | |
|
V83831 | HSD17B13-IN-80-d2 | 2770247-90-8 | |
|
V83878 | HSD17B13-IN-86 | 2770247-78-2 | |
|
V83921 | HSD17B13-IN-93 | 2848620-87-9 | |
|
V143845 | Rapirosiran sodium scrambled negative control | The Rapirosiran sodium scrambled negative control is a negative control with the sequence of Rapirosiran sodium scrambled. |